What's next for Biogen Idec
565353
If Biogen Idec Inc. is sold to a pharmaceuticals giant, as many biotech industry observers expect, it could spell the loss of yet another major corporate headquarters in Massachusetts, a blow to the state's prestige.
16443
Biogen and Elan receive an additional approval for Tysabri.
132487
For those that missed it last night, Biogen Idec (BIIB:Nasdaq - news - research) and Elan Pharmaceuticals (ELN:NYSE ADR - news - research) received FDA approval for their new multiple sclerosis drug, now called Tysabri (formerly known as Antegren.
267375
Investors in the biotechnology company Biogen Idec announced Wednesday that it had not received any definitive offers after putting itself up for sale two months ago.
249246
Genentech and Biogen Idec's drug shows positive results against multiple sclerosis.
289071
Today was a day of good news for multiple sclerosis patients: FDA granted approval to a new anti-multiple sclerosis drug Antegren developed by Biogen Idec Inc.
407294
The biotech company announces new drug delays.
688654
SensiGen LLC, a biotechnology company focused on the development and  commercialization of advanced gene-based molecular diagnostics announced  the appointment of Dr. Jay Stoerker to the position of Vice President of  Product Development.
113986
The Food and Drug Administration strongly endorsed Biogen Idec Inc.&#39;s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share.
182389
After a quiet year for biotechnology, a sudden wave of mergers and buyouts has sparked interest in a business that relies on deal-making to put the stamp of success on new ideas.
736084
Biogen Idec Inc.  said on  Thursday that fourth-quarter earnings rose on higher sales of  its cancer and multiple sclerosis drugs.
234249
Moving to strengthen its offerings to treat cancer, Biogen Idec Inc. of Cambridge yesterday signed a deal to license tumor-killing technology from ImmunoGen Inc.
427900
BOSTON  Â Biogen Idec said on Wednesday its fourth-quarter profit rose 84 percent, topping expectations, driven by increased sales of its multiple sclerosis drugs Avonex and Tysabri.
683001
Patients taking an experimental multiple sclerosis drug developed by Biogen Idec Inc.  and Elan Corp.  experienced far fewer relapses in a clinical trial, data that analysts say could give the drug a dominant market position.
172409
Forget genetic engineering. The new idea is synthetic biology, an effort to rewire the genetic circuitry of living organisms.
307878
It&#39;s made by Biogen Idec and Elan. It was orginally called, Antegren until the US Food and Drug Administration requested a name change, to avoid confusion with other drugs.
723657
Could a jointly marketed drug lead to a joint company? Ireland&#39;s Sunday Tribune said yesterday that US pharmaceuticals company Biogen Idec (nasdaq: BIIB - news - people ) was looking to make an all-stock bid